| Literature DB >> 29186163 |
Philip J Domeyer1, Vassilis Aletras1,2, Fotios Anagnostopoulos1,3, Vasiliki Katsari4, Dimitris Niakas1,5.
Abstract
INTRODUCTION: The use of generic medicines is a cost-effective policy, often dictated by fiscal restraints. To our knowledge, no fully validated tool exploring the students' knowledge and attitudes towards generic medicines exists. The aim of our study was to develop and validate a questionnaire exploring the knowledge and attitudes of M.Sc. in Health Care Management students and recent alumni's towards generic drugs in Greece.Entities:
Mesh:
Year: 2017 PMID: 29186163 PMCID: PMC5706728 DOI: 10.1371/journal.pone.0188484
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Sociodemographic characteristics of the study sample.
| Variables | N (%) |
|---|---|
| Male | 366 (37.1%) |
| Female | 620 (62.9%) |
| Single | 313 (31.7%) |
| Married | 628 (63.7%) |
| Divorced | 42 (4.3%) |
| Widowed | 3 (0.3%) |
| Employed | 938 (95.1%) |
| Unemployed | 48 (4.9%) |
| Doctor | 270 (27.4%) |
| Dentist | 32 (3.2%) |
| Pharmacist | 36 (3.6%) |
| Nurse | 194 (19.7%) |
| Other health professional | 266 (27.0%) |
| Other profession | 188 (19.1%) |
| Students | 716 (72.6%) |
| Graduates | 270 (27.4%) |
Descriptive statistics of the items.
| Item | Description | Mean±SD | Median (IQR) |
|---|---|---|---|
| I know what generic medications are | 1.502±0.795 | 1 (1) | |
| I know the difference between generics and brand name medications | 1.526±0.771 | 1 (1) | |
| A brand name and a generic medication contain the same active substance | 1.583±0.903 | 1 (1) | |
| The potency of generic and brand name medications is the same | 2.466±1.125 | 2 (1) | |
| The safety of generic and brand name medications is the same | 2.756±1.109 | 3 (2) | |
| The production standards of generic and brand name medications are the same | 2.903±1.124 | 3 (2) | |
| The price of generic medications is considerably lower than brand name medications | 1.843±0.975 | 2 (1) | |
| Substitution of brand-name with generic medicines can also be done by pharmacists | 3.516±1.368 | 4 (3) | |
| Substitution of brand-name with generic medicines should only be done by doctors | 1.861±1.130 | 1 (1) | |
| I believe that the use of generic medicines will reduce any relationships between doctors and pharmaceutical companies against the rules | 2.848±1.298 | 3 (2) | |
| I believe that the use of generic medicines will reduce the total cost of therapy | 2.205±1.061 | 2 (2) | |
| I would trust more a brand name than a generic medicine | 2.258±1.105 | 2 (2) | |
| I would trust more a doctor who would prescribe me a brand-name rather than a generic medicine | 3.128±1.134 | 3 (2) | |
| I am skeptical about generic medicines because of their lower price | 3.647±1.074 | 4 (1) | |
| I believe that generics were invented and promoted in order to resolve the financial crisis of social security institutions at the expense of citizens | 3.267±1.251 | 3 (2) | |
| Generic medicines have more undesirable effects (side-effects) than brand name medicines | 3.215±1.107 | 3 (1) | |
| The Greek authorities are able to detect possible irregularities in the production of generic medicines | 3.402±1.139 | 4 (1) | |
| The Greek authorities are able to detect in time and retract batches of generic drugs with reduced potency and/or safety | 3.427±1.113 | 4 (1) | |
| In case of ineffectiveness of Greek authorities, European authorities are capable of detecting possible irregularities in potency and/or safety of generic medicines in the Greek market | 2.924±1.054 | 3 (2) | |
| I would be worried if my medication was changed from brand-name to generic | 2.907±1.204 | 3 (2) |
a IQR, Interquartile range
Factor analysis with polychoric correlations (rotated factor loadings).
| Item | Factor 1 | Factor 2 | Factor 3 | Factor 4 | Factor 5 | Factor 6 |
|---|---|---|---|---|---|---|
| 0.016 | -0.045 | 0.031 | 0.006 | 0.017 | ||
| 0.009 | -0.046 | -0.065 | 0.105 | -0.023 | ||
| -0.021 | 0.408 | -0.033 | -0.083 | 0.104 | ||
| -0.097 | -0.076 | 0.125 | -0.019 | -0.033 | ||
| -0.098 | 0.050 | -0.056 | -0.016 | 0.0002 | ||
| -0.068 | 0.129 | 0.052 | 0.019 | -0.017 | ||
| 0.113 | 0.105 | 0.055 | 0.201 | -0.078 | ||
| 0.105 | 0.049 | 0.071 | 0.062 | -0.002 | ||
| -0.093 | -0.071 | -0.042 | -0.023 | 0.036 | ||
| -0.124 | 0.019 | 0.011 | -0.180 | 0.193 | ||
| -0.131 | 0.080 | -0.020 | 0.095 | -0.024 | ||
| -0.278 | 0.031 | -0.042 | 0.130 | 0.026 | ||
| 0.027 | 0.040 | -0.108 | 0.084 | 0.006 | ||
| 0.099 | -0.083 | 0.099 | -0.262 | 0.011 | ||
| -0.022 | -0.020 | 0.152 | -0.154 | -0.047 | ||
| -0.300 | 0.036 | 0.018 | 0.064 | -0.020 | ||
| 0.042 | 0.017 | 0.012 | 0.018 | -0.024 | ||
| 0.018 | 0.023 | -0.045 | -0.057 | 0.052 | ||
| -0.118 | -0.021 | 0.091 | 0.004 | -0.043 | ||
| -0.057 | -0.006 | -0.139 | -0.055 | 0.010 |
a Numbers in bold indicate the highest factor loadings for each item.
b Due to negative factor loading, item was inversely recoded
Factors correlation matrix in exploratory factor analysis with oblique rotation.
| Factor | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| 1 | ||||||
| -0.614 | 1 | |||||
| -0.318 | 0.348 | 1 | ||||
| -0.301 | 0.527 | 0.463 | 1 | |||
| -0.378 | 0.399 | -0.021 | 0.006 | 1 | ||
| -0.380 | 0.252 | 0.186 | 0.240 | 0.091 | 1 |
Squared multiple correlations (R2) for each observed variable of the model.
| Scale/item | R2 |
|---|---|
| 12 | 0.468 |
| 13 | 0.406 |
| 16 | 0.566 |
| 20 | 0.711 |
| 4 | 0.444 |
| 5 | 0.737 |
| 6 | 0.585 |
| 17 | 0.741 |
| 18 | 0.741 |
| 19 | 0.417 |
| 7 | 0.248 |
| 10 | 0.415 |
| 11 | 0.584 |
| 1 | 0.219 |
| 2 | 0.278 |
| 3 | 0.792 |
| 8 | 0.491 |
| 9 | 0.672 |
Internal consistency reliability and scale scores.
| Item | Scale/item description | Cronbach’s Alpha | Mean±SD | Median (IQR) |
|---|---|---|---|---|
| 0.821 | 2.83±0.896 | 2.75 (1.250) | ||
| “I would trust more a brand name than a generic medicine” | 0.876 | 2.18±1.082 | 2 (2) | |
| “I would trust more a doctor who would prescribe me a brand-name rather than a generic medicine” | 0.794 | 3.06±1.114 | 3 (2) | |
| “Generic medicines have more undesirable effects (side-effects) than brand name medicines” | 0.766 | 3.20±1.074 | 3 (1) | |
| “I would be worried if my medication was changed from brand-name to generic” | 0.885 | 2.88±1.153 | 3 (2) | |
| 0.805 | 2.71±0.938 | 2.67 (1.333) | ||
| “The potency of generic and brand name medications is the same” | 0.843 | 2.45±1.104 | 2 (1) | |
| “The safety of generic and brand name medications is the same” | 0.898 | 2.74±1.096 | 3 (2) | |
| “The production standards of generic and brand name medications are the same” | 0.915 | 2.94±1.116 | 3 (2) | |
| 0.847 | 3.19±0.993 | 3.33 (1.333) | ||
| “The Greek authorities are able to detect possible irregularities in the production of generic medicines” | 0.956 | 3.35±1.165 | 4 (1) | |
| “The Greek authorities are able to detect in time and retract batches of generic drugs with reduced potency and/or safety” | 0.958 | 3.35±1.141 | 4 (1) | |
| “In case of ineffectiveness of Greek authorities, European authorities are capable of detecting possible irregularities in potency and/or safety of generic medicines in the Greek market. | 0.880 | 2.88±1.064 | 3 (2) | |
| 0.655 | 2.29±0.855 | 2.33 (1) | ||
| “The price of generic medications is considerably lower than brand name medications” | 0.814 | 1.86±1.018 | 2 (1) | |
| “I believe that the use of generic medicines will reduce any relationships between doctors and pharmaceutical companies against the rules” | 0.855 | 2.83±1.251 | 3 (2) | |
| “I believe that the use of generic medicines will reduce the total cost of therapy” | 0.886 | 2.18±1.051 | 2 (2) | |
| 0.777 | 1.57±0.712 | 1.33 (1) | ||
| “I know what generic medications are” | 0.919 | 1.53±0.822 | 1 (1) | |
| “I know the difference between generics and brand name medications” | 0.934 | 1.53±0.777 | 1 (1) | |
| “A brand name and a generic medication contain the same active substance” | 0.855 | 1.65±0.959 | 1 (1) | |
| 0.719 | 3.89±1.079 | 4 (2) | ||
| “Substitution of brand-name with generic medicines can also be done by pharmacists” | 0.942 | 3.54±1.348 | 4 (3) | |
| “Substitution of brand-name with generic medicines should only be done by doctors” | 0.924 | 4.23±1.080 | 5 (1) |
a IQR, Interquartile range
b Cronbach’s alpha for summary scale
Multi-trait analysis with polychoric correlations.
| Scale/item | Item-Scale Correlations | |||||
|---|---|---|---|---|---|---|
| Trust | Drug quality | State audit | Fiscal impact | Knowledge | Drug substitution | |
| 0.671 | -0.516 | -0.227 | -0.279 | -0.116 | -0.199 | |
| 0.626 | -0.384 | -0.176 | -0.272 | -0.174 | -0.156 | |
| 0.661 | -0.533 | -0.198 | -0.313 | -0.226 | -0.182 | |
| 0.743 | -0.591 | -0.266 | -0.307 | -0.263 | -0.216 | |
| -0.481 | 0.634 | 0.172 | 0.267 | 0.352 | 0.184 | |
| -0.611 | 0.753 | 0.374 | 0.344 | 0.356 | 0.219 | |
| -0.500 | 0.711 | 0.419 | 0.392 | 0.274 | 0.186 | |
| -0.283 | 0.365 | 0.864 | 0.363 | 0.086 | 0.191 | |
| -0.267 | 0.356 | 0.870 | 0.336 | 0.062 | 0.146 | |
| -0.168 | 0.266 | 0.632 | 0.297 | 0.075 | 0.130 | |
| -0.191 | 0.284 | 0.291 | 0.443 | 0.124 | 0.100 | |
| -0.313 | 0.310 | 0.292 | 0.520 | 0.005 | 0.269 | |
| -0.353 | 0.347 | 0.305 | 0.623 | 0.168 | 0.202 | |
| -0.184 | 0.256 | 0.067 | 0.039 | 0.771 | -0.003 | |
| -0.178 | 0.274 | 0.064 | -0.011 | 0.822 | -0.001 | |
| -0.305 | 0.481 | 0.066 | 0.141 | 0.612 | 0.046 | |
| -0.153 | 0.208 | 0.198 | 0.252 | 0.061 | 0.680 | |
| -0.283 | 0.238 | 0.090 | 0.199 | 0.041 | 0.680 | |
a Pearson and Spearman correlations were also calculated, with similar outcomes (results not shown)